Vicki L. Sato - May 26, 2021 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
May 26, 2021
Transactions value $
-$108,911
Form type
4
Date filed
5/28/2021, 04:03 PM
Previous filing
May 25, 2021
Next filing
Jun 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$58K -894 -0.66% $64.90 135K May 26, 2021 Direct F1, F2, F3
transaction DNLI Common Stock Sale -$48.2K -732 -0.54% $65.88 134K May 26, 2021 Direct F1, F3, F4
transaction DNLI Common Stock Sale -$2.67K -40 -0.03% $66.72 134K May 26, 2021 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $64.58 to $65.57 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 3,253 restricted stock units.
F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $65.60 to $66.53 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $66.60 to 66.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.